Immune checkpoint inhibitor-bullous pemphigoid is characterized by interleukin-4 and interleukin-13 expression and responds to dupilumab treatment.
William D ShipmanKatelyn SinghJeffrey M CohenJonathan LeventhalWilliam E DamskyMary M TomaykoPublished in: The British journal of dermatology (2023)